Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A leading developer and manufacturer of life science technologies, products, and services for research, drug discovery, bioproduction, and preclinical testing. Operations are conducted globally with a focus on two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The company serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and Contract Research Organizations (CROs).
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenues | $94,135 | $112,250 |
| Gross Profit | $54,766 | $66,071 |
| Gross Margin | 58.2% | 58.9% |
| Operating Loss | $(6,211) | $1,894 (Income) |
| Net Loss | $(12,405) | $(3,415) |
| Cash from Operating Activities | $1,440 | $14,028 |
| Cash and Cash Equivalents (End of Period) | $4,108 | $4,283 |
| Total Debt Outstanding | $37,400 | $37,100 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 16.1% to $94.1 million, primarily due to softening worldwide demand from distributors, CROs, and academic institutions.
- Profitability Deterioration: The company shifted from an operating income of $1.9 million in 2023 to an operating loss of $6.2 million in 2024. Net loss widened significantly to $12.4 million.
- Cash Flow Contraction: Cash provided by operating activities dropped 89.7% to $1.4 million, driven by a larger net loss and changes in operating assets/liabilities, partially offset by $3.2 million in Employee Retention Tax Credit (ERTC) refunds.
- Debt Covenant Breach: The company was not in compliance with the consolidated net leverage ratio covenant as of December 31, 2024.
- One-Time Items: Included a $1.6 million loss on the sale of equity securities (HRGN shares) and $0.8 million in restructuring costs.
Guidance, Outlook, Risks, and Contingencies
Going Concern and Liquidity
The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. The company has $37.4 million in indebtedness and was in default of its credit agreement covenants. On March 10, 2025, the company entered into an amendment waiving the non-compliance, but this waiver is conditional on achieving specific refinancing milestones by June 30, 2025. Failure to refinance by this date will constitute an event of default, potentially making all debt immediately due and payable.
Internal Control Weaknesses
Management identified material weaknesses in internal controls over financial reporting as of December 31, 2024, specifically regarding the order-to-cash cycle and physical inventory counts. Consequently, disclosure controls and procedures were deemed ineffective.
Strategic Outlook
Management is exploring alternative capital sources to refinance debt. The company continues restructuring efforts, including headcount reductions and ERP consolidation, to improve cost structure. No specific financial guidance for 2025 was provided in the text.
Investor Verification Checklist
- Refinancing Status: Verify if the company has secured a term sheet or commitment letter for refinancing by the April 30, 2025, milestone to avoid default.
- Liquidity Runway: Assess current cash burn rates against the $4.1 million cash balance to determine solvency if refinancing is delayed.
- Internal Control Remediation: Review progress on remediation plans for material weaknesses in revenue recognition and inventory controls.
- ERTC Audit Risk: Confirm the status of the Employee Retention Tax Credit refunds ($3.2M received in 2024, $1.0M in Jan 2025), as these are subject to audit until May 2028.
- Goodwill Impairment: Monitor stock price performance; the filing notes that subsequent declines in stock price could trigger future goodwill impairment charges.